Ann: NTCELL Project Update, page-2

Great announcement.

This will settle the nerves (hopefully) of some longer-term investors' commentary recently, that there is no plan and no direction forthcoming from the new BOD.

It appears that the BOD is going down the same "Transformational Business Route" that I have talked about so often on another company thread.

Transformational strategies that can be applied to drive growth, innovation, and competitiveness.

Some key considerations for a transformational strategy are;

1. Research and Development (R&D) Innovation: Biotech companies heavily rely on research and development to drive scientific breakthroughs and develop new therapies, drugs, or biotechnological solutions. A transformational strategy could involve investing in cutting-edge R&D technologies, collaborating with academic institutions or other biotech companies, and exploring emerging fields or therapeutic areas. Such as Associate Professor Thomas Kimber("His research work focusses on the development of novel therapeutic approaches for the management of Parkinson’s disease and related disorders") and also Professor Glenda Halliday, of The University of Sydney ( who "has successfully worked with many Australian and international researchers on important scientific questions on Parkinson’s disease, alcohol toxicity, dementia with Lewy bodies, frontotemporal dementias, and motor neurodegenerative diseases." and also Professor Robert Kapsa, of RMIT University ( whose "experience ranges from tissue regeneration, molecular biology, gene therapy, biochemistry and he has been the lead investigator on a number of national and international (USA and Europe) projects dealing with use of polymers for tissue engineering, particularly for nerve and muscle, and gene editing-based autologous regenerative medicine solutions for hereditary nerve and muscle dysfunction.

2. Intellectual Property and Licensing: Biotech companies often have valuable intellectual property (IP) in the form of patents, trademarks, or proprietary technologies. A transformational strategy may involve actively managing and monetizing the IP portfolio through licensing agreements, partnerships, or spin-offs to maximize its value and create additional revenue streams.

3. Regulatory and Market Access Strategies: Biotech companies face stringent regulatory frameworks and market access challenges. A transformational strategy could involve actively engaging with regulatory authorities, optimizing the regulatory approval process, and developing strong market access strategies to ensure the successful commercialization of products. Professor Ali Abbas, "has 20 years’ experience in the field of Process Systems Engineering, with expertise in process
   intensification and design, techno-economic feasibility, process scale-up / optimal operation, with applications spanning biotechnology, biomedical systems to low-emissions technologies, and circular economy. He has published more than 140 papers in international scientific and engineering journals. Ali provides consultations to industry and government, and is active in commercialization activities, developing breakthrough deep technologies across multiple industry sectors in his capacity as company Founder and Director."

4. Strategic Partnerships and Collaborations: Collaboration is crucial in the biotech industry. Forming strategic partnerships with pharmaceutical companies, contract research organizations (CROs), such as Associate Professor Tina Soulis from https://alithialifesciences.com/ academic institutions, or government agencies can provide access to resources, expertise, and funding. These collaborations can accelerate product development, enhance manufacturing capabilities, and expand market reach.

5. Digital Transformation and Data Analytics: The integration of digital technologies and data analytics can bring significant benefits to biotech companies. Implementing digital solutions for data management, bioinformatics, clinical trials, or supply chain optimization can improve operational efficiency, accelerate decision-making, and drive innovation in areas such as precision medicine or personalized therapies.

6. Talent Acquisition and Retention: Biotech companies require specialized talent in scientific research, clinical trials, regulatory affairs, and commercialization. A transformational strategy could involve attracting and retaining top talent through competitive compensation packages, fostering a culture of innovation and collaboration, and providing opportunities for professional development.

7. Sustainability and Environmental Impact: Biotech companies can integrate sustainability practices into their transformational strategies. This could include adopting eco-friendly manufacturing processes, reducing waste and carbon emissions, or developing bio-based alternatives to traditional products or processes.
   
   Today we can see that the BOD has setup NT Cell for a Review
   "LCT has appointed an esteemed scientific advisory board to provide ongoing expert advice for the successful
   development of the NTCELL project. Consultants on the advisory board (above-mentioned) share their opinions on matters concerning the NTCELL program following their review of prior clinical trial data achieved from the first and second NTCELL clinical trials. Their opinions will shape the scientific review being undertaken by LCT"
   
   Hopefully, this will set up the NTC cell for future success.
   
   IMO The Advisory Board appointments fit nicely with the Transformational Strategy points 1,3 and 4 with some overlap into points 5, 6 & 7.
   
   I am sure the BOD experience will cover the other point 2, intellectual property in the not-too-distant future.

Good luck to all holders